Evaluation of Engraftment and Adverse Effects of Granulocyte Colony Stimulating Factor versus PEG Granulocyte Colony Stimulating Factor in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation GCSF vs. PEG-GCS Effects on Engraftment in HSCT
Iranian Journal of Pharmaceutical Sciences,
Vol. 17 No. 1 (2021),
15 January 2021
,
Page 99-106
https://doi.org/10.22037/ijps.v17.40303
Abstract
Hematopoietic stem cell transplantation (HSCT) is an effective treatment for many hematological malignancies. Engraftment is the foremost step in the autologous hematopoietic stem cell transplantation (AHSCT) process in which different granulocyte colony-stimulating factors with various administrations are used. In this study, we evaluated and compared the efficacy and side effects of two forms of recombinant granulocyte colony-stimulating growth factors (GCSF) ,GCSF and Peg GCSF, In this randomized clinical trial, 60 consecutive patients with multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma who underwent AHSCT were included, the average age of the patients was 55; the patients were then divided into two groups so the comparison of efficacy and side effects between the two methods become achievable. The local ethical committee approved the study with the code of SB2019:210291, and the Helsinki declaration was respected across the study. In the first group, patients received peg GCSF at a dose of 6 mg on day five, and the second group received GCSF started with 5μg/kg from day 5. We compared engraftment time and adverse effects in the two groups. Our study demonstrated no difference between the two groups regarding need for transfusion and infection complications; also, the two groups did not differ in terms of the flue-like syndrome, the type of infection and the recorded number of febrile neutropenia. Mean leukocyte engraftment days were 10.97 ± 1 and 11.1 ± 1.1 that was similar in both groups (P=0.328). Mean platelet engraftment days were 11.03 ± 2.4 and 11.1 ± 2.4 without significant difference (P=0.714).it was concluded that Pegfilgrastim has the same efficacy and safety profile in comparison to Filgrastim. Therefore, since Pegfilgrastim has a easier method of injection and can simplify the HSCT process.
- Stem Cell Transplantation
- GCSF
- PEG-GCSF
- Engraftment
- Adverse Effect
- Autologous
- HSCT
How to Cite
References
[2] Chua HL, Plett PA, Sampson CH, Katz BP, Carnathan GW, MacVittie TJ et al. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health. Phys. (2014) 106:21-38.
[3] Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs. (2003) 14:259-64.
[4] Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin. Oncol. (2004) 31:27-34.
[5] Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br. J. Haematol. (2006) 133:533-7.
[6] Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A , Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica (2005) 90:225-231.
[7] Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté Cet al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplant. ( 2006 ) 38:413-6.
[8] Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumors. Bone Marrow Transplant. (2009) 43:927-34.
[9] Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. (2006) 46:180-5.
[10] Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. (2007) 39:743-50.
[11] Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Single-dose Pegfilgrastim is comparable to daily Filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann. Hematol. (2009) 88:673-80.
[12] Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp. Hematol. (2006) 34:382-8.
[13] Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL et al. Retrospective comparison of the effects of Filgrastim and Pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant. (2010) 45:1522-7.
[14] Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G et al. Pegfilgrastim compared with Filgrastim after high-dose Melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur. J. Haematol. (2006) 77:410-5.
[15] Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. International Pegfilgrastim 749 Study Group: a randomized double-blind multicenter phase III study of fixed-dose single-administration Pegfilgrastim versus daily Filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. (2003) 14:29-35.
[16] Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant. ( 2005) 35:1165-9.
[17] Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaugheyD, Zhan F et al. Pegfilgrastim appears equivalent to daily dosing of Filgrastim to treat neutropenia after autologous peripheral blood stem
cell transplntation in patients with non-Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk. (2010) 10:186-91.
- Abstract Viewed: 110 times
- IJPS_Volume 17_Issue 1_Pages 99-106 Downloaded: 35 times